Total A beta(42)/A beta(40) ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
James D Doecke, Virginia Perez-Grijalba, Noelia Fandos, Christopher Fowler, Victor L Villemagne, Colin L Masters, Pedro Pesini, Manuel Sarasa
Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020
OBJECTIVE: To explore whether the plasma total β-amyloid (Aβ) Aβ42/Aβ40 ratio is a reliable predictor of the amyloid-PET status by exploring the association between these 2 variables in a subset of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging cohort. METHODS: Taking plasma samples at 3 separate time points, month 18 (n = 176), month 36 (n = 169), and month 54 (n = 135), we assessed the total Aβ42/Aβ40 ratio in plasma (TP42/40) with regard to neocortical Aβ burden via PET standardized uptake value ratio (SUVR) and investigated both association with Aβ-PET status and correlation (and agreement) with SUVR. RESULTS: The TP42/40 plasma ratio was significantly reduced in ..View full abstract
This work has been financed by Araclon Biotech Ltd.